SHOX2 gene methylation in Egyptians having lung cancer

Mohamed Mostafa Mohamed Ahmed Rizk, Suzan Mohamed Farouk Helal, Ahmed Youssef Shaaban Gad, Doreen Nazeih Assaad Younan and Salma Abd El Maguid Mohamed Ramadan Moemen

Abstract

Background: Lung cancer tumorigenesis is mainly due to accumulation of genetic and epigenetic events in the respiratory epithelium. Epigenetic alteration is more frequent than somatic mutation in lung cancer. CpG island methylation of homeobox-associated genes is commonly seen in most early stage tumors. This study aimed at examining the potential usefulness of DNA methylation biomarker SHOX2, in broncho-alveolar lavage, in the diagnosis of lung cancer. Broncho-alveolar lavage was obtained from 80 patients; 60 cases with lung masses (proved malignant by histopathology) and 20 age and gender matched patients with benign lung lesions (benign controls). SHOX2 methylation status was evaluated using methylation analysis by restriction endonuclease digestion and real-time PCR.

Results: SHOX2 methylation level ranged 3.90–77.16% in cases, and 3.52–7.86% in controls, (p ≤ 0.001). SHOX2 methylation levels in comparison to tissue biopsy pathology (the gold standard test) had 76.92% sensitivity, 70% specificity, 87% positive predictive value, and 53.8% negative predictive value in diagnosing lung cancer. Different methylation levels were noted in different lung pathologies, (p = 0.003), with the highest methylation levels in squamous cell carcinoma followed by adenocarcinoma and anaplastic carcinoma then lastly carcinoma in situ.

Conclusions: SHOX2 methylation levels could differentiate different varieties of lung cancer from benign lung lesions.

Keywords: SHOX2, Lung cancer, Egyptians, Methylation

Background

For several decades, lung cancer has been the world’s most common malignancy particularly among males [1, 2]. Many risk factors contribute to the pathogenesis of lung cancer, e.g., smoking as well as exposure to radon, asbestos, diesel, and ionizing radiation [3].

Lung cancer is classified according to its histo-pathology into two broad classes: non-small cell lung carcinoma (NSCLC), the most common type, and small cell lung carcinoma (SCLC), the second most common type. Along with these 2 main types of lung cancer, other rare types may occur including: carcinoid, adenoid cystic carcinomas, hamartomas, lymphomas, and sarcomas [4, 5].

Chest X-ray and computerized tomography (CT) are usually the first clue for diagnosing lung malignancy. They also play an important role in lung cancer staging. Bronchoscopy together with cytology and histological diagnosis provide optimal diagnosis [6, 7].

Tumor markers have a great importance in screening for early malignancy, helping in diagnosing different types of cancer, determining prognosis, following up patients after surgery, and monitoring therapeutic response. Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA), and pro-gastrin-releasing peptide (proGRP) can all be used with varying accuracies [8].

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Lung cancer tumorigenesis is mainly due to accumulation of genetic and epigenetic events in the respiratory epithelium. Epigenetic alteration is more frequent than somatic mutation in lung cancer [9, 10]. Since promoter hypermethylation can start early in lung carcinogenesis, it may thus have an important role in its early detection [11].

Detection of some of these early changes could be achieved by minimally invasive sample collection techniques, where aberrant DNA methylation can be detected as is the case with: sputum, broncho-alveolar lavage (BAL), and saliva of patients with lung cancer [12].

Short Stature Homeobox 2 (SHOX2) is a member of the homeobox family of genes and is known as SHOX homologous gene on chromosome three (SHOT), OG12, and OG12X [13, 14]. SHOX2 gene encodes an intranuclear transcription factor. SHOX2 CpG hypermethylation influences gene expression, which could affect the expression of multiple genes regulated by SHOX2, therefore promoting cell carcinogenesis. Genomic gain on chromosome 3q, where SHOX2 is located, has been recognized as one of the most prevalent and significant alterations in lung cancer [15].

The objective of this study is to determine the potential usefulness of SHOX2 DNA methylation in BAL as a biomarker for diagnosing lung cancer, which could be used for gene-targeted therapy. We also aimed at comparing these levels with other diagnostic modalities, like histopathology to detect their diagnostic accuracy.

**Methods**

The study design was a prospective case-control study conducted on 80 BAL samples obtained from 80 adult patients admitted to the Respiratory Department, sixty of whom had a suspicious lung mass on chest CT, which was later confirmed to be malignant by BAL cytology and/or histopathology of lung biopsy obtained by different techniques, e.g., CT-guided biopsy, ultrasound-guided biopsy, trans-bronchial biopsy, or open biopsy. Patients had neither co-existing malignancies, lung metastases, history of chemotherapy nor previous lung malignancy. Twenty patients with benign lung lesions (e.g., foreign body aspiration, tracheal web, etc.), matched for age and gender, served as a control group, all had undergone bronchoscopy and BAL but did not show any evidence of lung cancer by CT or cytology/histopathology. Detailed clinical history including smoking habits, drug use was documented and full clinical examination, routine laboratory, and radiological investigations (chest X-ray or CT) were also performed. SHOX2 DNA methylation levels were detected using methylation analysis by restriction endonuclease digestion and real-time PCR.

The study was approved by Institutional Research Ethics Committee (#616.07) and a written informed consent was obtained from all participants before enrolment in the study. Patients were all coded and detailed information was stored confidentially. This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki and its later amendments) for experiments involving humans.

**Specimen collection**

All enrolled patients underwent flexible bronchoscopic examination to visualize the airways, assess the presence of endo-bronchial lesion, surgical accessibility for resection, obtain BAL for cytological analysis, and obtain tissue biopsy for histopathological examination. Broncho-alveolar lavage (BAL) samples were collected during bronchoscopy by aspiration from the region of the suspicious lesion after injecting 10–20 ml of isotonic saline solution. Cytology from BAL was done to confirm or exclude malignancy.

**DNA Extraction**

DNA extraction was performed from the BAL using QIAamp DNA blood mini kit 50 (QIAGEN, Germany, cat. # 51104) and measurement of DNA quantity and purity was determined using Nanodrop 2000 spectrophotometer.

**Digestion by Methylation Sensitive Restriction Enzymes**

The DNA samples were subjected to restriction digestion by EpiTect Methyl II DNA Restriction Kit (Qiagen cat. # 335452), which prepares genomic DNA samples for DNA methylation analysis using EpiTect Methyl II PCR Assay. The kit contains: restriction digestion buffer, enzyme A (methylation-sensitive) and enzyme B (methylation-dependent). Using the enzymes and buffer provided in the kit, 4 digests were performed in order to detect different methylated DNA fractions. The product of a mock digest (Mo) contains all of the input genomic DNA. The product of the methylation-sensitive (Ms) restriction enzyme mixture (enzyme A) digest contains methylated DNA sequences, while the product of the methylation-dependent (Md) restriction enzyme mixture (enzyme B) digest contains unmethylated DNA sequences. The product of a double digest (Msd) measures the background and the success of both enzymatic digestions.

Equal amounts of a genomic DNA (125 ng) were added to 4 separate tubes into which buffer (13 μl/tube) and the appropriate restriction enzyme combinations (0.5 μl/tube) were added. The mock digest (Mo) had no enzymes added, enzyme A was added to the methylation-sensitive restriction digest (Ms), enzyme B was added to the methylation-dependent restriction digest (Md), and both enzyme mixtures were added to the double digest (Msd). All digests were incubated at 37 °C for 6 h in a thermal
cyclers (Thermo Scientific Arakitik Thermocycler) and the enzymes were heat inactivated at 65 °C, for 20 min.

**Quantification of SHOX2 gene methylation percentage by real-time PCR**

After DNA samples were digested by restriction enzymes, SHOX2 gene methylation status was assessed using EpiTect Methyl II PCR Assay. The EpiTect Methyl II PCR Assay (Cat #/ID: 335452) was used to analyze the amount of DNA in each digest of each sample to determine the methylation status of CpG islands in SHOX2 gene. The kit included the following: (1) RT² SYBR Green ROX qPCR Mastermix (Qiagen catalogue number 330520) and (2) EpiTect Methylyk II qPCR primer Assay (Human SHOX2) (Qiagen catalogue number 335002).

The method employed by the EpiTect Methyl II PCR kit is based on the detection of the remaining input DNA after cleavage with a methylation-sensitive and/or a methylation-dependent restriction enzyme. These enzymes digest unmethylated and methylated DNA, respectively. Following digestion, the remaining DNA in each individual enzyme reaction was quantified by real-time PCR using primers that flank a promoter (gene) region of interest. The relative fractions of methylated and unmethylated DNA were subsequently determined by comparing the amount in each digest with that of a mock (no enzymes added) digest using a ΔCT method.

Briefly, input genomic DNA is aliquoted into four equal portions and subjected to mock (no enzyme), methylation-sensitive (MSRE), methylation-dependent (MDRE), and double (MSRE and MDRE) restriction endonuclease digestion (5 μl of each enzyme). After digestion, the enzyme digests (5 μl/tube) were mixed directly with qPCR master mix (12.5 μl/tube) and dispensed into a PCR tubes containing pre- aliquoted primer mixes (1 μl/tube). Real-time PCR (Stratagene MX 3000P) was carried out using specified cycling conditions, (Supplementary material).

The product of the mock (no enzyme) digestion represents the total amount of input DNA for real-time PCR detection. In the methylation-sensitive digestion (Ms) reaction, the MSRE will digest unmethylated and partially methylated DNA. The remaining hypermethylated DNA (DNA in which all CpG sites are methylated) was detected by real-time PCR. In the methylation-dependent digestion (Md) reaction, the MDRE preferentially digested methylated DNA. The remaining unmethylated DNA was detected by real-time PCR. In the double digestion (Msd) reaction, both enzymes were present, and all DNA molecules (both methylated and unmethylated) were digested. This reaction measures the background and the fraction of input DNA refractory to enzyme digestion.

EpiTect Methyl II PCR assays provide gene methylation status as percentage unmethylated (UM) and percentage methylated (M) fraction of input DNA. Unmethylated represents the fraction of input genomic DNA containing no methylated CpG sites in the amplified region of a gene. Methylated represents fraction of input genomic DNA containing two or more methylated CpG sites in the targeted region of a gene.

The raw ΔCT values were inserted into the data analysis spreadsheet provided by Qiagen (www.sabiosciences.com/dna_methylation_data_analysis.php), which automatically calculated the relative amount of methylated and unmethylated DNA fractions.

**Statistical analysis of the data**

Data was fed into a computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). Qualitative data was described using absolute values and percent. The Kolmogorov-Smirnov test was used to test the normality of distribution. Quantitative data was described as range (minimum and maximum), mean, standard deviation and median. Significance of the obtained results was judged at the 5% level.

Receiver operating characteristic (ROC) curve was generated by plotting sensitivity (true positive) on Y-axis versus 1-specificity (false positive) on X-axis at different cut-off values. The area under the ROC curve (AUC) denotes the diagnostic performance of the test. Area more than 50% gives acceptable performance with respect to 100%, as perfect accuracy [16].

**Results**

Patients and controls were matched for age and sex ($p = 0.114$, $p = 0.19$ respectively, Table 1), inclusion criterion. Smoking was significantly more prevalent among cases than controls ($p = 0.023$, Table 2). Table 3 presents the

| Table 1 Comparison between controls and cases regarding their demographic data | Controls (n = 20) | Cases (n = 60) | Test of sig. | $p$ |
|---|---|---|---|---|
| **Sex** | | | | |
| Male | 12 | 60.0 | 50 | 83.3 | $\chi^2 = 2.342$ FE $p = 0.190$ |
| Female | 8 | 40.0 | 10 | 16.7 | |
| **Age (years)** | | | | |
| Min. – Max. | 28.0–72.0 | 34.0–82.0 | $t = 1.688$ | 0.114 |
| Mean ± SD. | 53.20 ± 12.47 | 60.67 ± 10.96 | | |
| Median | 54.0 | 60.50 | | |

$\chi^2$: Chi square test, FE: Fisher exact, $t$: Student $t$ test, $p$: $p$ value for comparing between the two groups.

*Statistically significant at $p \leq 0.05$
common clinical presentations of the population studied (a single subject may have more than one complaint), Table 4 presents their CT findings and Table 5 presents their bronchoscopic findings.

BAL cytology was negative for malignant cells in all controls and in 26.7% of cases who were later proved to be positive for malignant cells by histopathology of lung biopsy (Table 6).

Table 7 demonstrates the biopsy histopathology results among cases and controls who were negative for malignancy, with 20% of them showing inflammatory changes.

There was a statistically significant difference between methylated and unmethylated percentage of \textit{SHOX2} gene between the two groups, where the percentage of methylated \textit{SHOX2} was significantly higher ($p < 0.001$) among lung cancer cases (21.18 ± 18.12) than controls (5.62 ± 1.80), as shown in Table 8.

Background methylation was found among controls; therefore, a receiver operating characteristic (ROC) curve was constructed, as shown in Fig. 1, to calculate the cut-off methylation value that discriminates between cases and controls.

A methylation cut-off value of 7.16% was calculated, methylation values of more than 7.16% were considered positive. Methylation levels were ~77% sensitive, 70% specific with a positive predictive value of 87% and a negative predictive value of ~54% in detecting malignancy confirmed by histopathology biopsy (Table 9).

There was no statistical difference when comparing \textit{SHOX2} methylation levels between negative BAL cytology cases (16/60) and positive BAL cytology cases (44/60). The range of methylation of \textit{SHOX2} in cytology negative cases was 7.14–18.5%, (11.93 ± 5.33%) and a median of 10.11%, whereas \textit{SHOX2} methylation range in

| Table 2 | Comparison between controls and cases regarding their smoking status |
|---------|---------------------------------------------------------------|
| Smoking status | Controls ($n = 20$) | Cases ($n = 60$) | $\chi^2$ MC $p$ |
| Non-smoker | 14 70.0 | 14 23.3 | 6.989 0.023 |
| Smoker | 4 20.0 | 38 63.3 |
| Ex-smoker | 2 10.0 | 8 13.3 |

$\chi^2$: Chi square test, MC: Monte Carlo, $p$: $p$ value for comparing between the two groups.

*Statistically significant at $p \leq 0.05$.

| Table 4 | Comparison between controls and cases regarding their CT findings |
|---------|---------------------------------------------------------------|
| CT findings | Controls ($n = 20$) | Cases ($n = 60$) | $\chi^2$ $p$ |
| Normal | 4 20.0 | 0 0.0 | 6.316 $\ni$ $p = 0.058$ |
| Abnormal | 16 80.0 | 60 100.0 |
| Lesion | Lung mass | 2 12.5 | 44 73.3 | 18.133 $\ni$ $p = 0.001$ |
| | Lung mass & nodules | 0 0.0 | 8 13.3 |
| | Nodules | 4 25 6 10.0 |
| | Consolidation | 2 12.5 | 2 3.3 |
| | Cavalty lesion | 2 12.5 0 0.0 |
| | Bronchiectasis | 2 12.5 0 0.0 |
| | Foreign body | 4 25 0 0.0 |

| Side | Left | 2 12.5 | 32 53.3 | 6.164 $\ni$ $p = 0.037$ |
| | Right | 10 62.5 | 26 43.3 |
| | Bilateral | 4 25.0 | 2 3.3 |

$\chi^2$: Chi square test, MC: Monte Carlo, FE: Fisher exact, $p$: $p$ value for comparing between the two groups.

*Statistically significant at $p \leq 0.05$.

| Table 3 | Comparison between controls and cases regarding their clinical presentation |
|---------|---------------------------------------------------------------|
| Clinical presentation | Controls ($n = 20$) | Cases ($n = 60$) |
| Dyspnea/difficult breathing | 4 20.0 | 42 70.0 |
| Cough | 6 30.0 | 38 63.3 |
| Hemoptysis | 6 30.0 | 18 30.0 |
| Chest pain | 2 10.0 | 12 20.0 |
| Diabetes mellitus | 2 10.0 | 8 13.3 |
| Hypertension | 2 10.0 | 4 6.7 |
| Weight loss | 0 0.0 | 2 3.3 |
| Alleged foreign body aspiration | 4 20.0 | 0 0.0 |
| Fungal infection | 2 10.0 | 0 0.0 |

NB: a single subject may have more than one complaint.

| Table 5 | Comparison between controls and cases regarding their bronchoscopic findings |
|---------|---------------------------------------------------------------|
| Bronchoscopic findings | Controls ($n = 20$) | Cases ($n = 60$) |
| Mass | 2 10.0 | 44 73.3 |
| Inflammation | 8 40.0 | 6 10 |
| Nodules | 0 0.0 | 4 6.7 |
| Mass + bleeds on touch | 0 0.0 | 4 6.7 |
| Mass + inflammation | 0 0.0 | 2 3.3 |
| Tracheal web | 2 10.0 | 0 0.0 |
| Abscess | 2 10.0 | 0 0.0 |
| Bronchiectasis | 2 10.0 | 0 0.0 |
| Foreign body | 4 20.0 | 0 0.0 |
cytology positive cases was 3.9–77.16%, \( (23.96 \pm 19.73\%) \) with a median of 16.6. 3%.

Significantly different \( \text{SHOX2} \) methylation levels were noted among different lung cancer histopathological types \( (p = 0.03) \), as seen in Table 10. Highest methylation levels were found among squamous cell carcinoma (SCC) cases \( (40.61 \pm 1.18\%) \) with a median of 41.47%. The second highest levels of \( \text{SHOX2} \) methylation were found among adenocarcinoma cases \( (15.01 \pm 6.42\%) \) with a median of 15.67%. However, CIS cases had the least \( \text{SHOX2} \) methylation level \( (7.15 \pm 0.01\%) \) with a median of 7.15%.

### Discussion

To the best of our knowledge, this is the first study conducted on Egyptians comparing \( \text{SHOX2} \) gene methylation level between patients having lung cancer and those with benign lung lesions, aiming at investigating its relationship with lung cancer diagnosis. We studied \( \text{SHOX2} \) methylation status in 60 patients who proved to have lung cancer on histopathology, in addition to 20 patients with benign lung lesions who served as benign controls. This was achieved using real-time PCR after digestion by restriction enzymes, which were either methylation sensitive (Ms) or methylation dependant (Md).

In our studied patients with lung cancer, smoking was a prevalent risk factor in most of them, as previously reported by Schmidt et al. [17] and Ilse et al. [18], showing that smoking is a common risk factor for lung cancer.

In our study, methylation levels of \( \text{SHOX2} \) gene are expressed as percentages. \( \text{SHOX2} \) methylation percentages were found to be significantly higher among cases than controls, \( p < 0.001 \). Different \( \text{SHOX2} \) methylation levels are noted in different histopathological lung cancer types showing statistical significance.

### Table 6 Comparison between controls and cases regarding cytological analysis of BAL

| Cytology  | Controls \((n = 20)\) | Cases \((n = 60)\) | \(\chi^2\) | FE | \(p\) |
|-----------|----------------------|-------------------|---------|---|------|
| Negative  | 20 100.0             | 16 26.7           | 16.296  | <0.001* |
| Positive  | 0 0.0                | 44 73.3           |         |     |      |

\(\chi^2\): Chi square test, FE: Fisher exact, \(p\): \(p\) value for comparing between the two groups

*Statistically significant at \( p \leq 0.05 \)

### Table 7 Comparison between controls and cases regarding biopsy histopathology results

| Biopsy               | Controls \((n = 20)\) | Cases \((n = 60)\) | \(\chi^2\) | MC | \(p\) |
|----------------------|----------------------|-------------------|---------|---|------|
| Adenocarcinoma       | 0 0.0                | 24 40.0           | 34.064  | <0.001* |
| Squamous cell carcinoma | 0 0.0             | 18 30.0           |         |     |      |
| Anaplastic carcinoma | 0 0.0                | 10 16.7           |         |     |      |
| Carcinoma in situ    | 0 0.0                | 8 13.3            |         |     |      |
| Negative             | 16 80.0             | 0 0.0             |         |     |      |
| Nonspecific inflammation | 4 20.0         | 0 0.0             |         |     |      |

\(\chi^2\): Chi square test, MC: Monte Carlo, \(p\): \(p\) value for comparing between the two groups

*Statistically significant at \( p \leq 0.05 \)

### Table 8 Comparison between controls and cases regarding the percentage of \( \text{SHOX2} \) gene methylation

| Methylation percentage | Controls \((n = 20)\) | Cases \((n = 60)\) | Test of sig. \(p\) |
|------------------------|----------------------|-------------------|-------------------|
| Un-methylated \( \text{SHOX2} \) (%) | Min–Max | 92.14–96.48 | 22.84–96.10 | \(t = 4.324\) | <0.001* |
| Mean ± S.D.            | 94.38 ± 1.80         | 78.82 ± 18.12     |                  |
| Median                 | 94.92                | 84.34             |                  |
| Methylated \( \text{SHOX2} \) (%) | Min–Max | 3.52–7.86 | 3.90–77.16 | \(U = 23.50\) | <0.001* |
| Mean ± S.D.            | 5.62 ± 1.80          | 21.18 ± 18.12     |                  |
| Median                 | 5.08                 | 15.67             |                  |

\(U\): Mann Whitney test, \(t\): Student t test, \(p\): \(p\) value for comparing between the two groups

*Statistically significant at \( p \leq 0.05 \)

In our studied patients with lung cancer, smoking was a prevalent risk factor in most of them, as previously reported by Schmidt et al. [17] and Ilse et al. [18], showing that smoking is a common risk factor for lung cancer.

In our study, methylation levels of \( \text{SHOX2} \) gene are expressed as percentages. \( \text{SHOX2} \) methylation percentages were found to be significantly higher among cases than controls, \( p < 0.001 \). Different \( \text{SHOX2} \) methylation levels are noted in different histopathological lung cancer types showing statistical significance.
Statistically significant at p = 0.03. Highest methylation levels are found in SCC cases followed by adenocarcinoma, anaplastic carcinoma (SCLC), and lastly CIS. The cut-off point for positive methylation was calculated to be more than 7.16 by ROC curve.

Dietrich et al. [19], who used Epi proLung BL Reflex kit, established a cut-off for the test to differentiate between positive and negative cases; the cut-off value was 9.5%. Ilse et al. [18] used the same cut-off value, as they used the same kit. Also Schmidt et al. [17] implemented a methylation cut-off value to differentiate between positive and negative results, as background methylation was present in their control samples. Their methodology depended on bisulphite conversion followed by real-time PCR.

Schmidt et al. [17] found that higher methylation levels were noted in both SCLC and SCC than in patients with adenocarcinoma and this indicates a lower sensitivity of SHOX2 methylation in adenocarcinoma diagnosis. Another reason for the differences in methylation levels is the location of the tumor, as SCC masses are commonly centrally located, which makes BAL of better quality as it is accessible by bronchoscopy, opposite to peripherally located tumors such as adenocarcinoma.

Ilse et al. [18] showed that SCLC was best diagnosed by SHOX2 methylation percentage, with highest sensitivity 82%, followed by SCC at 81%, adenocarcinoma at 65%, adenocarcinoma NOS at 50%, but there was no significant difference in their study.

In our study, SHOX2 methylation levels showed a sensitivity of 76.92% and a specificity of 70% in detecting lung cancer cases. In the study conducted by Schmidt et al. [17], SHOX2 methylation levels showed a sensitivity of 68% and a specificity of 95%, while in that conducted by Dietrich et al. [19], SHOX2 methylation levels showed a sensitivity of 78% and a specificity of 96%, and lastly in the study of Ilse et al. [18], they showed a sensitivity of 64% and a specificity of 98%.

The difference between our results and those obtained by others may be attributed to the different methodologies used, difference in the number of studied cases, and ethnic differences between the studied populations.

The main limitations of our study are the relatively small sample size and inability to detect other epigenetic changes due to our limited budget. However, among the strong points in this research are the strict exclusion and inclusion criteria adopted for the selection of cases to avoid any confounding factors that could affect the results of our study causing bias.

Conclusions

In conclusion, the most common histological type of lung cancer among Egyptians enrolled in our study was adenocarcinoma followed by SCC then SCLC and lastly adenocarcinoma in situ. SHOX2 methylation levels could differentiate between lung cancer and benign lung lesions with a significant difference, p < 0.001. SHOX2 methylation levels differed significantly according to the histological types of tumors, highest in SCC, followed by adenocarcinoma then anaplastic carcinoma and lastly adenocarcinoma in situ. SHOX2 methylation level could not only distinguish between malignant and benign lung lesions but also discriminate between different histological types of lung cancer.

Interestingly, samples that were classified as “cytologically negative” or “inconclusive” due to the absence of malignant cells could be identified as cancer-positive based on their SHOX2 DNA methylation level.

### Table 9 Agreement (sensitivity, specificity) for methylated SHOX2 gene percentage to discriminate lung cancer cases from controls having benign lesions

| SHOX2 methylation level (%) | Cut-off | Sensitivity | Specificity | PPV | NPV |
|----------------------------|---------|-------------|-------------|-----|-----|
|                            | 7.16    | 76.92       | 70.0        | 87.0| 53.8|

**PPV** = Positive predictive value, **NPV** = Negative predictive value

### Table 10 Relation between histopathology and SHOX2 methylation % among the different lung cancer histopathological types (n = 60)

| Histopathology of lung biopsy (n = 60) | Squamous cell carcinoma (n = 18) | Adeno-carcinoma (n = 24) | Anaplastic carcinoma (n = 10) | Adeno-carcinoma in situ (n = 8) |
|---------------------------------------|---------------------------------|-------------------------|-------------------------------|--------------------------------|
| Min. – Max.                           | 8.97–77.16                      | 6.57–29.89              | 3.90–10.48                    | 7.14–7.16                      |
| Mean ± SD                             | 40.61 ± 1.18                    | 15.01 ± 6.42            | 7.85 ± 3.21                   | 7.15 ± 0.01                    |
| Median                                | 41.47                           | 15.67                   | 8.52                          | 7.15                          |

| **H** | **p** |
|-------|-------|
| 14.199² | 0.003³ |

*Statistically significant at p ≤ 0.05*
**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s43042-020-00069-1.

**Additional file 1: Table S1.** PCR cycling protocol.

**Abbreviations**

BAL: Broncho-alveolar lavage; CDKN2A/p16: Cyclin-dependent kinase inhibitor 2A/p16; CEA: Carcinoembryonic antigen; CISH: Carcino In situ; Cpg: Cytosine guanine islands; CT: Computerized tomography; CYFRA: Cytokeratin 19 fragment; DNA: Deoxyribonucleic acid; M: Methylated; Msd: Methylation-dependent; MSRE: Methylation-dependent restriction enzyme; MGMT: Methyl guanine DNA methyl transferase; Mo: Mock digest; Ms: Methylsensitive; Msd: Double digest; MSRE: Methylsensitive restriction enzyme; NOS: Not otherwise specified; NSCLC: Non-small cell lung carcinoma; NSE: Neuro-specific enolase; proGRP: Pro-gastrin-releasing peptide; PTPRN2: Protein tyrosine phosphatase receptor type N2; qPCR: Quantitative polymerase chain reaction; ROC: Receiver operating characteristic; ROS: Reactive oxygen species; SCC: Squamous cell carcinoma; SCCA: Squamous cell carcinoma antigen; SCLC: Small cell lung carcinoma; SHOT: SHOX homologous gene on chromosome three; SHOX2: Short stature homeobox 2; SPSS: Statistical package for social sciences; UM: Unmethylated

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MR designed the study. SH performed the pathological investigations. AG selected the patients. DY analyzed and interpreted the data and was a major contributor in writing the manuscript. SM performed the laboratory investigations, data analysis, and drafting the manuscript. The authors certify that each author has participated sufficiently in this research and takes full responsibility for the validity and objectivity of the entire study. All authors have approved the final version of the manuscript. Neither this manuscript nor one with similar content has been published or is being considered for publication in any language.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors and was completely funded by the authors.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article [and its supplementary information file].

**Ethics approval and consent to participate**

This study received ethical approval from the Institutional Research Ethics Committee of Alexandria University, Faculty of Medicine. Written informed consents were obtained from all participants before enrolment in the study. The identification information of all subjects was kept confidential and was protected from the public. This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki and its later amendments) for experiments involving humans.

**Consent for publication**

The authors certify that each author has participated sufficiently in this research and takes full responsibility for the validity and objectivity of the entire study.

**Competing interests**

The authors have nothing to disclose and report no conflict of interest, whether personal or financial.

**Author details**

1. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Khartoum Square, Azarita, Alexandria, Egypt. 2. Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 3. Pulmonology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

**References**

1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
2. Arieta O, Lazcano E (2019) Lung cancer: Epidemiology, diagnosis and treatment. Salud Publica Mex 61(3):217–218. https://doi.org/10.21149/10660
3. Zhong L, Goldberg MS, Parente MT, Hanley JA (2000) Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. Lung Cancer 27:13–18. https://doi.org/10.1016/s1050-0892(00)00093-8
4. Birring SS, Peake MD (2005) Symptoms and the early diagnosis of lung cancer. Thorax 60:268–269. https://doi.org/10.1136/thx.2004.03698
5. Beadsmoor CJ, Sreaton NJ (2003) Classification, staging and prognosis of lung cancer. Eur J Radiol 45:58–17. https://doi.org/10.1016/j.ejrad.2002.10.003

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors and was completely funded by the authors.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article [and its supplementary information file].

**Ethics approval and consent to participate**

This study received ethical approval from the Institutional Research Ethics Committee of Alexandria University, Faculty of Medicine. Written informed consents were obtained from all participants before enrolment in the study. The identification information of all subjects was kept confidential and was protected from the public. This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki and its later amendments) for experiments involving humans.

**Consent for publication**

The authors certify that each author has participated sufficiently in this research and takes full responsibility for the validity and objectivity of the entire study.

**Competing interests**

The authors have nothing to disclose and report no conflict of interest, whether personal or financial.

**Author details**

1. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Khartoum Square, Azarita, Alexandria, Egypt. 2. Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 3. Pulmonology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Received: 26 February 2020 Accepted: 27 May 2020
Published online: 01 July 2020

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.